X

    XORTX Therapeutics Inc (XRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.27
    -0.07 (-2.91%)

    Market Cap: $4.25M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(9/14)
    Avg Surprise
    -54.17%
    Streak
    6 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-1.05N/AN/ABeat-452.6%
    Mar 26
    		$-0.58N/AN/ABeat-205.6%
    Dec 25
    		$-0.09N/A+94.30%Beat+92.3%
    Sep 25
    		$-1.02$-1.58+35.44%Beat-404.5%
    Jun 25
    		$-0.19N/AN/ABeat+94.5%
    Mar 25
    		$-0.19$0.00N/ABeat+93.6%
    Dec 24
    		$-1.17$-2.08+43.75%Beat-84.0%
    Sep 24
    		$-0.20N/AN/ABeat+69.8%
    Jun 24
    		$-3.44$-4.61+25.38%Beat+18.7%
    Mar 24
    		$-2.96$-4.21+29.69%Beat+37.9%
    Dec 23
    		$-0.64$-0.81+21.96%Beat-218.0%
    Sep 23
    		$-0.67$-0.19-252.63%Miss-292.3%
    Jun 23
    		$-4.23N/A+62.40%Beat+63.8%
    Mar 23
    		$-4.77N/A+53.91%Beat+62.1%
    Dec 22
    		$-0.20$-0.27+25.93%Beat+71.3%
    Sep 22
    		$-0.17$-0.16-3.96%Miss-798.9%
    Jun 22
    		$-11.67$-11.25-3.73%Miss-5497.1%
    Mar 22
    		$-12.60$-9.90-27.27%Miss-457.3%
    Sep 21
    		$-0.70$-0.07-863.57%Miss-1409.1%
    Jun 21
    		$-0.02N/AN/ABeat+51.3%
    Mar 21
    		$-0.21N/AN/ABeat-4864.3%
    Dec 20
    		$-2.26N/AN/ABeat-87.6%
    Sep 20
    		$-0.05N/AN/ABeat+94.5%
    Jun 20
    		$-0.04N/AN/ABeat+96.0%
    Mar 20
    		$-0.00N/AN/ABeat+99.6%
    Dec 19
    		$-1.21N/AN/ABeat-28.6%
    Sep 19
    		$-0.84N/AN/ABeat-
    Jun 19
    		$-0.98N/AN/ABeat-
    Mar 19
    		$-0.97N/AN/ABeat-
    Dec 18
    		$-0.94N/AN/ABeat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    No dividend payments in the selected period.
    View XRTX's full dividend history

    Key Metrics

    Valuation
    P/E Ratio-0.83EV/EBITDA0.09x
    Price/FCF-0.45xFCF Yield-223.59%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-99.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.59xQuick Ratio3.59x
    Trading Statistics
    Beta0.08Avg Volume10.45K
    52-Week High$7.0552-Week Low$1.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.16
    SMA 20$2.15
    SMA 50$2.11
    SMA 200$2.41
    EMA 10$2.22
    EMA 20$2.17
    EMA 50$2.16
    EMA 200$2.56

    MACD

    Line: 0.05Signal: 0.02Hist: 0.03

    ADX

    ADX: 40.6+DI: 33.6-DI: 14.3

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down80.0
    PSAR$1.95

    Bollinger Bands

    Upper Band$2.39
    Lower Band$1.92
    %B Position2185%(Upper)
    Band Width0.75

    RSI (14-Day)

    Neutral
    56.1

    Momentum Oscillators

    Stoch %K62.0
    Stoch %D66.9
    Williams %R-48.4
    ROC (10d)10.2%
    Momentum0.21
    CCI (20d)89.9
    MFI (14d)55.9

    Volatility Measures

    ATR (14d)$0.16(7.2%)
    StdDev (20d)0.12
    Hist Vol74.4%(High)

    Volume Flow

    VWAP$2.27
    OBV173.3M
    AD Line5.1B
    CMF (20d)-0.084

    Volume Metrics

    Avg Vol (20d)10.8K
    Vol Ratio0.5x(Low)
    VWMA (20d)$2.22

    Pivot Points

    R3$2.55
    R2$2.50
    R1$2.42
    Pivot Point$2.36
    S1$2.28
    S2$2.22
    S3$2.14

    Advanced Oscillators

    TSI11.08
    Ultimate Osc53.2
    KST37.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$17,852$25,487$29,562$29,055$28,102$25,906$25,406$26,157$33,036$31,988$33,178$16,251
    Gross Profit$-17,852$-25,487$-29,562$-29,055$-28,102$-25,906$-25,406$-26,157$-33,036$-31,988$-33,178$-16,251
    Operating Expenses$1.63M$823,297$667,404$716,197$889,945$963,456$661,264$579,324$1.46M$585,917$983,674$1.10M
    R&D$111,038$33,113$55,707$57,011$186,751$276,309$7,763$34,741$67,683$73,643$182,689$569,713
    SG&A$0$621,873$495,109$392,939$465,827$477,795$407,034$546,633$817,912$512,146$484,847$510,109
    Operating Income$-1,647,718$-823,297$-696,967$-716,197$-889,945$-963,456$-661,264$-874,749$-3,121,494$-1,088,616N/A$-1,393,312
    Interest Income$0$1,635$3,922$7,201$12,326$18,421$0$29,023$35,952$31,602$0$63,614
    Interest Expense$82$0$0$0$0$0$0$0$0$16,188$0$0
    Income Before Tax$-1,647,800$-808,472$-599,538$-649,469$-717,700$-698,673$122,535$-587,011$170,066$-3,018,936$2.70M$-1,333,366
    Income Tax Expense$0$0$0$0$0$0$0$0$1$1.05M$-3,682,898$455,024
    Net Income$-1,647,800$-808,472$-599,538$-649,469$-717,700$-698,673$122,535$-587,011$170,066$-3,018,936$2.70M$-1,333,366
    EBITDA$-1,629,866$-797,452$-667,405$-686,812$-862,315$-937,471$-635,120$-848,800$-1,460,641$-1,056,484N/A$-1,376,845
    EBIT$-1,647,718$-823,297$-696,967$-716,197$-889,945$-963,456$-661,264$-874,749$-1,493,690$-1,088,616N/A$-1,393,312
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XRTX

    News

    Going-concern warning at XORTX (XRTX) as losses mount

    XORTX Therapeutics Inc. (XRTX) reported an interim net loss of $2.50 million for the six months ended June 30, 2026, widening from $1.42 million a year prior. The company's management has issued a going-concern warning, citing ongoing losses and a limited cash balance of $0.99 million against a monthly cash burn of approximately $296,000. Despite these financial challenges, XORTX acquired the VB4-P5 renal anti-fibrotic program and plans to prioritize its XRx-026 gout program and XRx-008 ADPKD program while actively seeking additional financing and partnerships.

    Stock Titan•8/17/26•
    Bearish

    XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo

    XORTX Therapeutics Inc. announced the resignation of its board chairman, Anthony Giovinazzo, effective July 31, 2026, due to personal reasons and other interests. Co-CEO Dr. Allen Davidoff praised Giovinazzo's leadership. Spark, TipRanks' AI Analyst, rated XRTX as Neutral due to weak financial performance despite low leverage and improving loss trends.

    The Globe and Mail•8/5/26•
    Neutral

    Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed

    XORTX Therapeutics announced that its director and board chair, Anthony Giovinazzo, is stepping down for personal reasons and to pursue other interests. The company expressed gratitude for his leadership and ethical contributions during his tenure. XORTX, a late-stage clinical pharmaceutical company, will continue to advance its pipeline, which includes therapies for gout and progressive kidney disease.

    Stock Titan•8/4/26•
    Neutral

    XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role

    XORTX Therapeutics Inc. announced the resignation of Anthony Giovinazzo from its board of directors. Giovinazzo served as chairman of the board for several years and is stepping down for personal reasons and to pursue other interests. The company acknowledged his significant contributions and leadership during his tenure.

    www.marketscreener.com•8/1/26•
    Neutral

    XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons

    XORTX Therapeutics Inc. announced that Anthony Giovinazzo has resigned from its board of directors for personal reasons and to pursue other interests. Co-CEO Dr. Allen Davidoff expressed gratitude for Giovinazzo's leadership and ethics during his tenure as chairman. XORTX remains focused on developing therapies for gout and progressive kidney disease, with several products in its clinical pipeline.

    Stock Titan•7/31/26•
    Neutral

    Frequently Asked Questions About XRTX

    Does XRTX pay dividends?
    XORTX Therapeutics Inc (XRTX) has a dividend payment track record. See the XRTX dividend history page for its current payment status, yield, and streaks.
    What is XRTX's market cap?
    XORTX Therapeutics Inc (XRTX) has a market capitalization of $4.25M with a current stock price of $2.27.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In